Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28,29,30]
The major key for nephrotoxicity is oxidative stress due to tissue inflammation
For example, encapsulation of Liraglutide, a long-acting GLP-1, in PLGA NPs significantly protected the drug from degradation in simulated gastric and intestinal fluids
Besides, GLP-1RA NLY01 could significantly reduce the proportion of infiltrating white blood cells (CD45 high ) and monocytes (Clec12a + ) in the central nervous system (CNS), while decreasing the number of effector/memory T cells (CD4 + CD44 + ) and inhibiting inflammation in peripheral circulation and CNS (90)
If the drugs couldnt help a lifter lift more, what was the upside for the rest of us